Hosted on MSN4h
Eli Lilly (LLY): Buy, Sell, or Hold Post Q4 Earnings?
Eli Lilly’s stock price fell to $872.91. Shareholders have lost 8.3% of their capital, which is disappointing considering the ...
Hosted on MSN14d
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 weight-loss drugs, Zepbound and Mounjaro, missed estimates for the second ...
Seeking Alpha1mon
Eli Lilly: Market Overreacted
Eli Lilly's Q4 FY24 guidance adjustment is due ... There are also some specific challenges related to the implementation of the Inflation Reduction Act (IRA) which come from the requirement ...
Seattle Times1mon
Wall Street mostly rises after encouraging inflation data despite Lilly’s drag
NEW YORK (AP) — Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential stocks kept indexes in check. The S&P 500 rose 0.1% ...
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
The Register-Herald1mon
Stock market today: Wall Street mostly rises after encouraging inflation data despite Lilly's drag
NEW YORK (AP) — Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential stocks kept indexes in check. The S&P 500 rose 0.1% ...